{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T07:13:30Z","timestamp":1781594010058,"version":"3.54.5"},"reference-count":81,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2023,2,9]],"date-time":"2023-02-09T00:00:00Z","timestamp":1675900800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,2,9]],"date-time":"2023-02-09T00:00:00Z","timestamp":1675900800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Urol Nephrol"],"DOI":"10.1007\/s11255-023-03474-8","type":"journal-article","created":{"date-parts":[[2023,2,10]],"date-time":"2023-02-10T02:14:13Z","timestamp":1675995253000},"page":"1735-1745","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Research progress of nephrotic syndrome accompanied by thromboembolism"],"prefix":"10.1007","volume":"55","author":[{"given":"Yajing","family":"Tian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baichao","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2899-7899","authenticated-orcid":false,"given":"Guangdong","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,2,9]]},"reference":[{"key":"3474_CR1","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1159\/000063768","volume":"22","author":"JS Cameron","year":"2002","unstructured":"Cameron JS, Hicks J (2002) The origins and development of the concept of a \u201cnephrotic syndrome.\u201d Am J Nephrol 22:240\u2013247. https:\/\/doi.org\/10.1159\/000063768","journal-title":"Am J Nephrol"},{"key":"3474_CR2","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1136\/bmj.39576.709711.80","volume":"336","author":"RP Hull","year":"2008","unstructured":"Hull RP, Goldsmith DJ (2008) Nephrotic syndrome in adults. BMJ 336:1185\u20131189. https:\/\/doi.org\/10.1136\/bmj.39576.709711.80","journal-title":"BMJ"},{"key":"3474_CR3","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.blre.2011.07.001","volume":"25","author":"S Pavord","year":"2011","unstructured":"Pavord S, Myers B (2011) Bleeding and thrombotic complications of kidney disease. Blood Rev 25:271\u2013278. https:\/\/doi.org\/10.1016\/j.blre.2011.07.001","journal-title":"Blood Rev"},{"key":"3474_CR4","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1056\/nejm199804233381707","volume":"338","author":"SR Orth","year":"1998","unstructured":"Orth SR, Ritz E (1998) The nephrotic syndrome. N Engl J Med 338:1202\u20131211. https:\/\/doi.org\/10.1056\/nejm199804233381707","journal-title":"N Engl J Med"},{"key":"3474_CR5","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1148\/radiol.14140121","volume":"273","author":"LJ Zhang","year":"2014","unstructured":"Zhang LJ, Zhang Z, Li SJ, Meinel FG, Nance JW Jr, Zhou CS, Zhao YE, Schoepf UJ, Lu GM (2014) Pulmonary embolism and renal vein thrombosis in patients with nephrotic syndrome: prospective evaluation of prevalence and risk factors with CT. Radiology 273:897\u2013906. https:\/\/doi.org\/10.1148\/radiol.14140121","journal-title":"Radiology"},{"key":"3474_CR6","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfaa134","author":"K Shinkawa","year":"2020","unstructured":"Shinkawa K, Yoshida S, Seki T, Yanagita M, Kawakami K (2020) Risk factors of venous thromboembolism in patients with nephrotic syndrome: a retrospective cohort study. Nephrol Dial Transplant. https:\/\/doi.org\/10.1093\/ndt\/gfaa134","journal-title":"Nephrol Dial Transplant"},{"key":"3474_CR7","doi-asserted-by":"publisher","first-page":"513","DOI":"10.2215\/cjn.10131011","volume":"7","author":"BA Kerlin","year":"2012","unstructured":"Kerlin BA, Ayoob R, Smoyer WE (2012) Epidemiology and pathophysiology of nephrotic syndrome-associated thromboembolic disease. Clin J Am Soc Nephrol 7:513\u2013520. https:\/\/doi.org\/10.2215\/cjn.10131011","journal-title":"Clin J Am Soc Nephrol"},{"key":"3474_CR8","doi-asserted-by":"publisher","first-page":"497","DOI":"10.4103\/jfmpc.jfmpc_1076_19","volume":"9","author":"AN Leslom","year":"2020","unstructured":"Leslom AN, Alrawiah ZMS, Al-Asmari AMA, Alqashaneen MDA, Alahmari AOT, Al-Ahmari H (2020) Prevalence of pulmonary thromboembolism in nephrotic syndrome patients: A systematic review and meta-analysis. J Family Med Prim Care 9:497\u2013501. https:\/\/doi.org\/10.4103\/jfmpc.jfmpc_1076_19","journal-title":"J Family Med Prim Care"},{"key":"3474_CR9","doi-asserted-by":"publisher","first-page":"814","DOI":"10.7326\/0003-4819-102-6-814","volume":"102","author":"AI Schafer","year":"1985","unstructured":"Schafer AI (1985) The hypercoagulable states. Ann Intern Med 102:814\u2013828. https:\/\/doi.org\/10.7326\/0003-4819-102-6-814","journal-title":"Ann Intern Med"},{"key":"3474_CR10","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1055\/s-0038-1646373","volume":"66","author":"B Dahlb\u00e4ck","year":"1991","unstructured":"Dahlb\u00e4ck B (1991) Protein S and C4b-binding protein: components involved in the regulation of the protein C anticoagulant system. Thromb Haemost 66:49\u201361","journal-title":"Thromb Haemost"},{"key":"3474_CR11","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1159\/000184351","volume":"46","author":"G Rostoker","year":"1987","unstructured":"Rostoker G, Goualt-Heilmann M, Levent M, Robeva R, Lang P, Lagrue G (1987) High level of protein C and protein S in nephrotic syndrome. Nephron 46:220\u2013221. https:\/\/doi.org\/10.1159\/000184351","journal-title":"Nephron"},{"key":"3474_CR12","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1055\/s-0038-1661225","volume":"53","author":"I Pabinger-Fasching","year":"1985","unstructured":"Pabinger-Fasching I, Lechner K, Niessner H, Schmidt P, Balzar E, Mannhalter C (1985) High levels of plasma protein C in nephrotic syndrome. Thromb Haemost 53:5\u20137","journal-title":"Thromb Haemost"},{"key":"3474_CR13","doi-asserted-by":"publisher","first-page":"42","DOI":"10.7326\/0003-4819-107-1-42","volume":"107","author":"S Vigano-D'Angelo","year":"1987","unstructured":"Vigano-D\u2019Angelo S, D\u2019Angelo A, Kaufman CE Jr, Sholer C, Esmon CT, Comp PC (1987) Protein S deficiency occurs in the nephrotic syndrome. Ann Intern Med 107:42\u201347. https:\/\/doi.org\/10.7326\/0003-4819-107-1-42","journal-title":"Ann Intern Med"},{"key":"3474_CR14","doi-asserted-by":"publisher","first-page":"9072","DOI":"10.1016\/S0021-9258(19)38813-1","volume":"265","author":"J Nishioka","year":"1990","unstructured":"Nishioka J, Suzuki K (1990) Inhibition of cofactor activity of protein S by a complex of protein S and C4b-binding protein. Evidence for inactive ternary complex formation between protein S, C4b-binding protein, and activated protein C. J Biol Chem 265:9072\u20139076","journal-title":"J Biol Chem"},{"key":"3474_CR15","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1016\/s0022-3476(80)80678-0","volume":"96","author":"SO Lau","year":"1980","unstructured":"Lau SO, Tkachuck JY, Hasegawa DK, Edson JR (1980) Plasminogen and antithrombin III deficiencies in the childhood nephrotic syndrome associated with plasminogenuria and antithrombinuria. J Pediatr 96:390\u2013392. https:\/\/doi.org\/10.1016\/s0022-3476(80)80678-0","journal-title":"J Pediatr"},{"key":"3474_CR16","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/0002-9343(78)90848-3","volume":"65","author":"RH Kauffmann","year":"1978","unstructured":"Kauffmann RH, Veltkamp JJ, Van Tilburg NH, Van Es LA (1978) Acquired antithrombin III deficiency and thrombosis in the nephrotic syndrome. Am J Med 65:607\u2013613. https:\/\/doi.org\/10.1016\/0002-9343(78)90848-3","journal-title":"Am J Med"},{"key":"3474_CR17","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1038\/ki.1985.149","volume":"28","author":"F Llach","year":"1985","unstructured":"Llach F (1985) Hypercoagulability, renal vein thrombosis, and other thrombotic complications of nephrotic syndrome. Kidney Int 28:429\u2013439. https:\/\/doi.org\/10.1038\/ki.1985.149","journal-title":"Kidney Int"},{"key":"3474_CR18","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1007\/s00467-015-3173-8","volume":"31","author":"B Eneman","year":"2016","unstructured":"Eneman B, Levtchenko E, van den Heuvel B, Van Geet C, Freson K (2016) Platelet abnormalities in nephrotic syndrome. Pediatr Nephrol 31:1267\u20131279. https:\/\/doi.org\/10.1007\/s00467-015-3173-8","journal-title":"Pediatr Nephrol"},{"key":"3474_CR19","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1038\/ki.1989.310","volume":"36","author":"C Machleidt","year":"1989","unstructured":"Machleidt C, Mettang T, St\u00e4rz E, Weber J, Risler T, Kuhlmann U (1989) Multifactorial genesis of enhanced platelet aggregability in patients with nephrotic syndrome. Kidney Int 36:1119\u20131124. https:\/\/doi.org\/10.1038\/ki.1989.310","journal-title":"Kidney Int"},{"key":"3474_CR20","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1182\/blood.V52.5.969.969","volume":"52","author":"N Yoshida","year":"1978","unstructured":"Yoshida N, Aoki N (1978) Release of arachidonic acid from human platelets. A key role for the potentiation of platelet aggregability in normal subjects as well as in those with nephrotic syndrome. Blood 52:969\u2013977","journal-title":"Blood"},{"key":"3474_CR21","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1111\/j.1365-2141.1982.tb03862.x","volume":"52","author":"CA Jackson","year":"1982","unstructured":"Jackson CA, Greaves M, Patterson AD, Brown CB, Preston FE (1982) Relationship between platelet aggregation, thromboxane synthesis and albumin concentration in nephrotic syndrome. Br J Haematol 52:69\u201377. https:\/\/doi.org\/10.1111\/j.1365-2141.1982.tb03862.x","journal-title":"Br J Haematol"},{"key":"3474_CR22","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1056\/nejm197402212900805","volume":"290","author":"AC Carvalho","year":"1974","unstructured":"Carvalho AC, Colman RW, Lees RS (1974) Platelet function in hyperlipoproteinemia. N Engl J Med 290:434\u2013438. https:\/\/doi.org\/10.1056\/nejm197402212900805","journal-title":"N Engl J Med"},{"key":"3474_CR23","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1038\/ki.1994.274","volume":"46","author":"TJ Rabelink","year":"1994","unstructured":"Rabelink TJ, Zwaginga JJ, Koomans HA, Sixma JJ (1994) Thrombosis and hemostasis in renal disease. Kidney Int 46:287\u2013296. https:\/\/doi.org\/10.1038\/ki.1994.274","journal-title":"Kidney Int"},{"key":"3474_CR24","doi-asserted-by":"publisher","first-page":"2677","DOI":"10.1111\/j.1538-7836.2003.0543b.x","volume":"1","author":"VA van Hylckama","year":"2003","unstructured":"van Hylckama VA, Rosendaal FR (2003) High levels of fibrinogen are associated with the risk of deep venous thrombosis mainly in the elderly. J Thromb Haemost 1:2677\u20132678. https:\/\/doi.org\/10.1111\/j.1538-7836.2003.0543b.x","journal-title":"J Thromb Haemost"},{"key":"3474_CR25","first-page":"41","volume":"26","author":"A Vay\u00e1","year":"2002","unstructured":"Vay\u00e1 A, Mira Y, Mart\u00ednez M, Villa P, Ferrando F, Estell\u00e9s A, Corella D, Aznar J (2002) Biological risk factors for deep vein trombosis. Clin Hemorheol Microcirc 26:41\u201353","journal-title":"Clin Hemorheol Microcirc"},{"key":"3474_CR26","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1046\/j.1523-1755.1998.00729.x","volume":"53","author":"MG de Sain Velden","year":"1998","unstructured":"de Sain Velden MG, Kaysen GA, de Meer K, Stellaard F, Voorbij HA, Reijngoud DJ, Rabelink TJ, Koomans HA (1998) Proportionate increase of fibrinogen and albumin synthesis in nephrotic patients: measurements with stable isotopes. Kidney Int 53:181\u20138. https:\/\/doi.org\/10.1046\/j.1523-1755.1998.00729.x","journal-title":"Kidney Int"},{"key":"3474_CR27","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1172\/jci116947","volume":"93","author":"JJ Zwaginga","year":"1994","unstructured":"Zwaginga JJ, Koomans HA, Sixma JJ, Rabelink TJ (1994) Thrombus formation and platelet-vessel wall interaction in the nephrotic syndrome under flow conditions. J Clin Invest 93:204\u2013211. https:\/\/doi.org\/10.1172\/jci116947","journal-title":"J Clin Invest"},{"key":"3474_CR28","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1055\/s-0038-1657351","volume":"49","author":"E McGinley","year":"1983","unstructured":"McGinley E, Lowe GD, Boulton-Jones M, Forbes CD, Prentice CR (1983) Blood viscosity and haemostasis in the nephrotic syndrome. Thromb Haemost 49:155\u2013157","journal-title":"Thromb Haemost"},{"key":"3474_CR29","first-page":"186","volume":"24","author":"XH Du","year":"1985","unstructured":"Du XH, Glas-Greenwalt P, Kant KS, Allen CM, Hayes S, Pollak VE (1985) Nephrotic syndrome with renal vein thrombosis: pathogenetic importance of a plasmin inhibitor (alpha 2-antiplasmin). Clin Nephrol 24:186\u2013191","journal-title":"Clin Nephrol"},{"key":"3474_CR30","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1055\/s-2007-996100","volume":"23","author":"N Schlegel","year":"1997","unstructured":"Schlegel N (1997) Thromboembolic risks and complications in nephrotic children. Semin Thromb Hemost 23:271\u2013280. https:\/\/doi.org\/10.1055\/s-2007-996100","journal-title":"Semin Thromb Hemost"},{"key":"3474_CR31","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1182\/blood.V82.2.392.392","volume":"82","author":"L Hervio","year":"1993","unstructured":"Hervio L, Chapman MJ, Thillet J, Loyau S, Angl\u00e9s-Cano E (1993) Does apolipoprotein(a) heterogeneity influence lipoprotein(a) effects on fibrinolysis? Blood 82:392\u2013397","journal-title":"Blood"},{"key":"3474_CR32","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/nrneph.2017.155","volume":"14","author":"S Agrawal","year":"2018","unstructured":"Agrawal S, Zaritsky JJ, Fornoni A, Smoyer WE (2018) Dyslipidaemia in nephrotic syndrome: mechanisms and treatment. Nat Rev Nephrol 14:57\u201370. https:\/\/doi.org\/10.1038\/nrneph.2017.155","journal-title":"Nat Rev Nephrol"},{"key":"3474_CR33","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/1047-2797(92)90033-m","volume":"2","author":"WP Castelli","year":"1992","unstructured":"Castelli WP, Anderson K, Wilson PW, Levy D (1992) Lipids and risk of coronary heart disease. The Framingham Study Ann Epidemiol 2:23\u201328. https:\/\/doi.org\/10.1016\/1047-2797(92)90033-m","journal-title":"The Framingham Study Ann Epidemiol"},{"key":"3474_CR34","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1038\/nm0907-1015","volume":"13","author":"SP Jackson","year":"2007","unstructured":"Jackson SP, Calkin AC (2007) The clot thickens\u2013oxidized lipids and thrombosis. Nat Med 13:1015\u20131016. https:\/\/doi.org\/10.1038\/nm0907-1015","journal-title":"Nat Med"},{"key":"3474_CR35","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1038\/nm1626","volume":"13","author":"EA Podrez","year":"2007","unstructured":"Podrez EA, Byzova TV, Febbraio M, Salomon RG, Ma Y, Valiyaveettil M, Poliakov E, Sun M, Finton PJ, Curtis BR, Chen J, Zhang R, Silverstein RL, Hazen SL (2007) Platelet CD36 links hyperlipidemia, oxidant stress and a prothrombotic phenotype. Nat Med 13:1086\u20131095. https:\/\/doi.org\/10.1038\/nm1626","journal-title":"Nat Med"},{"key":"3474_CR36","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1097\/01.Gim.0000067987.77803.D0","volume":"5","author":"LM Reich","year":"2003","unstructured":"Reich LM, Bower M, Key NS (2003) Role of the geneticist in testing and counseling for inherited thrombophilia. Genet Med 5:133\u2013143. https:\/\/doi.org\/10.1097\/01.Gim.0000067987.77803.D0","journal-title":"Genet Med"},{"key":"3474_CR37","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1038\/s41588-019-0519-3","volume":"51","author":"D Klarin","year":"2019","unstructured":"Klarin D, Busenkell E, Judy R, Lynch J, Levin M, Haessler J, Aragam K, Chaffin M, Haas M, Lindstr\u00f6m S, Assimes TL, Huang J, Min Lee K, Shao Q, Huffman JE, Kabrhel C, Huang Y, Sun YV, Vujkovic M, Saleheen D, Miller DR, Reaven P, DuVall S, Boden WE, Pyarajan S, Reiner AP, Tr\u00e9gou\u00ebt DA, Henke P, Kooperberg C, Gaziano JM, Concato J, Rader DJ, Cho K, Chang KM, Wilson PWF, Smith NL, O\u2019Donnell CJ, Tsao PS, Kathiresan S, Obi A, Damrauer SM, Natarajan P (2019) Genome-wide association analysis of venous thromboembolism identifies new risk loci and genetic overlap with arterial vascular disease. Nat Genet 51:1574\u20131579. https:\/\/doi.org\/10.1038\/s41588-019-0519-3","journal-title":"Nat Genet"},{"key":"3474_CR38","doi-asserted-by":"publisher","DOI":"10.3390\/medicina56050242","author":"G Ismail","year":"2020","unstructured":"Ismail G, Obri\u0219c\u0103 B, Jurubi\u021b\u0103 R, Andronesi A, Sorohan B, H\u00e2rza M (2020) Inherited risk factors of thromboembolic events in patients with primary nephrotic syndrome. Medicina (Kaunas). https:\/\/doi.org\/10.3390\/medicina56050242","journal-title":"Medicina (Kaunas)"},{"key":"3474_CR39","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1111\/jth.13190","volume":"14","author":"E van der Pol","year":"2016","unstructured":"van der Pol E, B\u00f6ing AN, Gool EL, Nieuwland R (2016) Recent developments in the nomenclature, presence, isolation, detection and clinical impact of extracellular vesicles. J Thromb Haemost 14:48\u201356. https:\/\/doi.org\/10.1111\/jth.13190","journal-title":"J Thromb Haemost"},{"key":"3474_CR40","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1083\/jcb.201211138","volume":"200","author":"G Raposo","year":"2013","unstructured":"Raposo G, Stoorvogel W (2013) Extracellular vesicles: exosomes, microvesicles, and friends. J Cell Biol 200:373\u2013383. https:\/\/doi.org\/10.1083\/jcb.201211138","journal-title":"J Cell Biol"},{"key":"3474_CR41","doi-asserted-by":"publisher","first-page":"171","DOI":"10.3390\/ijms17020171","volume":"17","author":"N Iraci","year":"2016","unstructured":"Iraci N, Leonardi T, Gessler F, Vega B, Pluchino S (2016) Focus on extracellular vesicles: physiological role and signalling properties of extracellular membrane vesicles. Int J Mol Sci 17:171. https:\/\/doi.org\/10.3390\/ijms17020171","journal-title":"Int J Mol Sci"},{"key":"3474_CR42","doi-asserted-by":"publisher","first-page":"470","DOI":"10.3904\/kjim.2019.108","volume":"34","author":"SH Kwon","year":"2019","unstructured":"Kwon SH (2019) Extracellular vesicles in renal physiology and clinical applications for renal disease. Korean J Intern Med 34:470\u2013479. https:\/\/doi.org\/10.3904\/kjim.2019.108","journal-title":"Korean J Intern Med"},{"key":"3474_CR43","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1161\/circresaha.110.233056","volume":"108","author":"AP Owens 3rd","year":"2011","unstructured":"Owens AP 3rd, Mackman N (2011) Microparticles in hemostasis and thrombosis. Circ Res 108:1284\u20131297. https:\/\/doi.org\/10.1161\/circresaha.110.233056","journal-title":"Circ Res"},{"key":"3474_CR44","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1038\/nrneph.2017.98","volume":"13","author":"D Karpman","year":"2017","unstructured":"Karpman D, St\u00e5hl AL, Arvidsson I (2017) Extracellular vesicles in renal disease. Nat Rev Nephrol 13:545\u2013562. https:\/\/doi.org\/10.1038\/nrneph.2017.98","journal-title":"Nat Rev Nephrol"},{"key":"3474_CR45","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1182\/blood.V89.4.1121","volume":"89","author":"RF Zwaal","year":"1997","unstructured":"Zwaal RF, Schroit AJ (1997) Pathophysiologic implications of membrane phospholipid asymmetry in blood cells. Blood 89:1121\u20131132","journal-title":"Blood"},{"key":"3474_CR46","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1161\/atvbaha.109.200956","volume":"31","author":"O Morel","year":"2011","unstructured":"Morel O, Jesel L, Freyssinet JM, Toti F (2011) Cellular mechanisms underlying the formation of circulating microparticles. Arterioscler Thromb Vasc Biol 31:15\u201326. https:\/\/doi.org\/10.1161\/atvbaha.109.200956","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"3474_CR47","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1152\/physrev.00020.2015","volume":"96","author":"EM Bevers","year":"2016","unstructured":"Bevers EM, Williamson PL (2016) Getting to the outer leaflet: physiology of phosphatidylserine exposure at the plasma membrane. Physiol Rev 96:605\u2013645. https:\/\/doi.org\/10.1152\/physrev.00020.2015","journal-title":"Physiol Rev"},{"key":"3474_CR48","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1160\/th11-09-0673","volume":"107","author":"C Gao","year":"2012","unstructured":"Gao C, Xie R, Yu C, Wang Q, Shi F, Yao C, Xie R, Zhou J, Gilbert GE, Shi J (2012) Procoagulant activity of erythrocytes and platelets through phosphatidylserine exposure and microparticles release in patients with nephrotic syndrome. Thromb Haemost 107:681\u2013689. https:\/\/doi.org\/10.1160\/th11-09-0673","journal-title":"Thromb Haemost"},{"key":"3474_CR49","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1093\/ndt\/gfw227","volume":"32","author":"G Gyamlani","year":"2017","unstructured":"Gyamlani G, Molnar MZ, Lu JL, Sumida K, Kalantar-Zadeh K, Kovesdy CP (2017) Association of serum albumin level and venous thromboembolic events in a large cohort of patients with nephrotic syndrome. Nephrol Dial Transplant 32:157\u2013164. https:\/\/doi.org\/10.1093\/ndt\/gfw227","journal-title":"Nephrol Dial Transplant"},{"key":"3474_CR50","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1038\/ki.2011.312","volume":"81","author":"SJ Barbour","year":"2012","unstructured":"Barbour SJ, Greenwald A, Djurdjev O, Levin A, Hladunewich MA, Nachman PH, Hogan SL, Cattran DC, Reich HN (2012) Disease-specific risk of venous thromboembolic events is increased in idiopathic glomerulonephritis. Kidney Int 81:190\u2013195. https:\/\/doi.org\/10.1038\/ki.2011.312","journal-title":"Kidney Int"},{"key":"3474_CR51","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1186\/s12882-019-1336-8","volume":"20","author":"S Kelddal","year":"2019","unstructured":"Kelddal S, Nykj\u00e6r KM, Gregersen JW, Birn H (2019) Prophylactic anticoagulation in nephrotic syndrome prevents thromboembolic complications. BMC Nephrol 20:139. https:\/\/doi.org\/10.1186\/s12882-019-1336-8","journal-title":"BMC Nephrol"},{"key":"3474_CR52","doi-asserted-by":"publisher","first-page":"478","DOI":"10.2215\/cjn.07190713","volume":"9","author":"N Medjeral-Thomas","year":"2014","unstructured":"Medjeral-Thomas N, Ziaj S, Condon M, Galliford J, Levy J, Cairns T, Griffith M (2014) Retrospective analysis of a novel regimen for the prevention of venous thromboembolism in nephrotic syndrome. Clin J Am Soc Nephrol 9:478\u2013483. https:\/\/doi.org\/10.2215\/cjn.07190713","journal-title":"Clin J Am Soc Nephrol"},{"key":"3474_CR53","first-page":"555","volume":"54","author":"M H\u00e2rza","year":"2013","unstructured":"H\u00e2rza M, Ismail G, Mitroi G, Gherghiceanu M, Preda A, Mircescu G, Sinescu I (2013) Histological diagnosis and risk of renal vein thrombosis, and other thrombotic complications in primitive nephrotic syndrome. Rom J Morphol Embryol 54:555\u2013560","journal-title":"Rom J Morphol Embryol"},{"key":"3474_CR54","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/j.ekir.2019.12.001","volume":"5","author":"R Lin","year":"2020","unstructured":"Lin R, McDonald G, Jolly T, Batten A, Chacko B (2020) A Systematic review of prophylactic anticoagulation in nephrotic syndrome. Kidney Int Rep 5:435\u2013447. https:\/\/doi.org\/10.1016\/j.ekir.2019.12.001","journal-title":"Kidney Int Rep"},{"key":"3474_CR55","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1038\/ki.2013.476","volume":"85","author":"T Lee","year":"2014","unstructured":"Lee T, Biddle AK, Lionaki S, Derebail VK, Barbour SJ, Tannous S, Hladunewich MA, Hu Y, Poulton CJ, Mahoney SL, Charles Jennette J, Hogan SL, Falk RJ, Cattran DC, Reich HN, Nachman PH (2014) Personalized prophylactic anticoagulation decision analysis in patients with membranous nephropathy. Kidney Int 85:1412\u20131420. https:\/\/doi.org\/10.1038\/ki.2013.476","journal-title":"Kidney Int"},{"key":"3474_CR56","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1038\/kisup.2012.20","volume":"2","author":"Kidney Disease: Improving Global Outcomes (KDIGO) Glomerulonephritis Work Group","year":"2012","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) Glomerulonephritis Work Group (2012) KDIGO clinical practice guideline for glomerulonephritis. Kidney Int Suppl 2:139\u2013274. https:\/\/doi.org\/10.1038\/kisup.2012.20","journal-title":"Kidney Int Suppl"},{"key":"3474_CR57","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.kint.2021.05.021","volume":"100","author":"Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group","year":"2021","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group (2021) KDIGO 2021 clinical practice guideline for the management of glomerular diseases. Kidney Int 100:S1-s276. https:\/\/doi.org\/10.1016\/j.kint.2021.05.021","journal-title":"Kidney Int"},{"key":"3474_CR58","doi-asserted-by":"publisher","first-page":"64s","DOI":"10.1378\/chest.119.1_suppl.64s","volume":"119","author":"J Hirsh","year":"2001","unstructured":"Hirsh J, Warkentin TE, Shaughnessy SG, Anand SS, Halperin JL, Raschke R, Granger C, Ohman EM, Dalen JE (2001) Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest 119:64s\u201394s. https:\/\/doi.org\/10.1378\/chest.119.1_suppl.64s","journal-title":"Chest"},{"key":"3474_CR59","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1016\/j.kint.2019.11.027","volume":"97","author":"VK Derebail","year":"2020","unstructured":"Derebail VK, Rheault MN, Kerlin BA (2020) Role of direct oral anticoagulants in patients with kidney disease. Kidney Int 97:664\u2013675. https:\/\/doi.org\/10.1016\/j.kint.2019.11.027","journal-title":"Kidney Int"},{"key":"3474_CR60","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1056\/nejm199709043371007","volume":"337","author":"JI Weitz","year":"1997","unstructured":"Weitz JI (1997) Low-molecular-weight heparins. N Engl J Med 337:688\u2013698. https:\/\/doi.org\/10.1056\/nejm199709043371007","journal-title":"N Engl J Med"},{"key":"3474_CR61","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10235709","author":"A Matyjek","year":"2021","unstructured":"Matyjek A, Rymarz A, Nowicka Z, Literacki S, Rozmyslowicz T, Niemczyk S (2021) Anti-Xa activity of enoxaparin for prevention of venous thromboembolism in severe nephrotic syndrome-a single center prospective study. J Clin Med. https:\/\/doi.org\/10.3390\/jcm10235709","journal-title":"J Clin Med"},{"key":"3474_CR62","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/S0021-9258(18)89728-9","volume":"260","author":"OP Malhotra","year":"1985","unstructured":"Malhotra OP, Nesheim ME, Mann KG (1985) The kinetics of activation of normal and gamma-carboxyglutamic acid-deficient prothrombins. J Biol Chem 260:279\u2013287","journal-title":"J Biol Chem"},{"key":"3474_CR63","doi-asserted-by":"publisher","first-page":"5648","DOI":"10.1016\/S0021-9258(17)33107-1","volume":"251","author":"GL Nelsestuen","year":"1976","unstructured":"Nelsestuen GL (1976) Role of gamma-carboxyglutamic acid. An unusual protein transition required for the calcium-dependent binding of prothrombin to phospholipid. J Biol Chem 251:5648\u20135656","journal-title":"J Biol Chem"},{"key":"3474_CR64","doi-asserted-by":"publisher","first-page":"523","DOI":"10.18553\/jmcp.2011.17.7.523","volume":"17","author":"ME Kleinow","year":"2011","unstructured":"Kleinow ME, Garwood CL, Clemente JL, Whittaker P (2011) Effect of chronic kidney disease on warfarin management in a pharmacist-managed anticoagulation clinic. J Manag Care Pharm 17:523\u201330. https:\/\/doi.org\/10.18553\/jmcp.2011.17.7.523","journal-title":"J Manag Care Pharm"},{"key":"3474_CR65","first-page":"75","volume":"25","author":"D Ganeval","year":"1986","unstructured":"Ganeval D, Fischer AM, Barre J, Pertuiset N, Dautzenberg MD, Jungers P, Houin G (1986) Pharmacokinetics of warfarin in the nephrotic syndrome and effect on vitamin K-dependent clotting factors. Clin Nephrol 25:75\u201380","journal-title":"Clin Nephrol"},{"key":"3474_CR66","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1161\/circresaha.112.276741","volume":"111","author":"CH Yeh","year":"2012","unstructured":"Yeh CH, Fredenburgh JC, Weitz JI (2012) Oral direct factor Xa inhibitors. Circ Res 111:1069\u20131078. https:\/\/doi.org\/10.1161\/circresaha.112.276741","journal-title":"Circ Res"},{"key":"3474_CR67","doi-asserted-by":"publisher","first-page":"4208","DOI":"10.1093\/eurheartj\/ehx003","volume":"39","author":"L Mazzolai","year":"2018","unstructured":"Mazzolai L, Aboyans V, Ageno W, Agnelli G, Alatri A, Bauersachs R, Brekelmans MPA, B\u00fcller HR, Elias A, Farge D, Konstantinides S, Palareti G, Prandoni P, Righini M, Torbicki A, Vlachopoulos C, Brodmann M (2018) Diagnosis and management of acute deep vein thrombosis: a joint consensus document from the european society of cardiology working groups of aorta and peripheral vascular diseases and pulmonary circulation and right ventricular function. Eur Heart J 39:4208\u20134218. https:\/\/doi.org\/10.1093\/eurheartj\/ehx003","journal-title":"Eur Heart J"},{"key":"3474_CR68","doi-asserted-by":"publisher","first-page":"e44S","DOI":"10.1378\/chest.11-2292","volume":"141","author":"W Ageno","year":"2012","unstructured":"Ageno W, Gallus AS, Wittkowsky A, Crowther M, Hylek EM, Palareti G (2012) Oral anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: american college of chest physicians evidence-based clinical practice guidelines. Chest 141:e44S-e88S. https:\/\/doi.org\/10.1378\/chest.11-2292","journal-title":"Chest"},{"key":"3474_CR69","doi-asserted-by":"publisher","first-page":"967","DOI":"10.2147\/tcrm.S84210","volume":"11","author":"YH Mekaj","year":"2015","unstructured":"Mekaj YH, Mekaj AY, Duci SB, Miftari EI (2015) New oral anticoagulants: their advantages and disadvantages compared with vitamin K antagonists in the prevention and treatment of patients with thromboembolic events. Ther Clin Risk Manag 11:967\u2013977. https:\/\/doi.org\/10.2147\/tcrm.S84210","journal-title":"Ther Clin Risk Manag"},{"key":"3474_CR70","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1182\/asheducation-2013.1.464","volume":"2013","author":"KA Bauer","year":"2013","unstructured":"Bauer KA (2013) Pros and cons of new oral anticoagulants. Hematology Am Soc Hematol Educ Program 2013:464\u2013470. https:\/\/doi.org\/10.1182\/asheducation-2013.1.464","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"3474_CR71","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/1477-9560-11-10","volume":"11","author":"W Mueck","year":"2013","unstructured":"Mueck W, Schwers S, Stampfuss J (2013) Rivaroxaban and other novel oral anticoagulants: pharmacokinetics in healthy subjects, specific patient populations and relevance of coagulation monitoring. Thromb J 11:10. https:\/\/doi.org\/10.1186\/1477-9560-11-10","journal-title":"Thromb J"},{"key":"3474_CR72","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1016\/j.clinthera.2017.05.358","volume":"39","author":"AR Almutairi","year":"2017","unstructured":"Almutairi AR, Zhou L, Gellad WF, Lee JK, Slack MK, Martin JR, Lo-Ciganic WH (2017) Effectiveness and safety of non-vitamin K antagonist oral anticoagulants for atrial fibrillation and venous thromboembolism: a systematic review and meta-analyses. Clin Ther 39:1456-1478.e36. https:\/\/doi.org\/10.1016\/j.clinthera.2017.05.358","journal-title":"Clin Ther"},{"key":"3474_CR73","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1002\/ajh.25475","volume":"94","author":"A Cuker","year":"2019","unstructured":"Cuker A, Burnett A, Triller D, Crowther M, Ansell J, Van Cott EM, Wirth D, Kaatz S (2019) Reversal of direct oral anticoagulants: guidance from the anticoagulation forum. Am J Hematol 94:697\u2013709. https:\/\/doi.org\/10.1002\/ajh.25475","journal-title":"Am J Hematol"},{"key":"3474_CR74","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1177\/1060028014549349","volume":"48","author":"LH Dupree","year":"2014","unstructured":"Dupree LH, Reddy P (2014) Use of rivaroxaban in a patient with history of nephrotic syndrome and hypercoagulability. Ann Pharmacother 48:1655\u20131658. https:\/\/doi.org\/10.1177\/1060028014549349","journal-title":"Ann Pharmacother"},{"key":"3474_CR75","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.2169\/internalmedicine.8742-16","volume":"56","author":"Y Shimada","year":"2017","unstructured":"Shimada Y, Nagaba Y, Nagaba H, Kamata M, Murano J, Kamata F, Okina C, Nonoguchi H, Shimada H, Takeuchi Y (2017) Edoxaban was effective for treating renal vein thrombosis in a patient with nephrotic syndrome. Intern Med 56:2307\u20132310. https:\/\/doi.org\/10.2169\/internalmedicine.8742-16","journal-title":"Intern Med"},{"key":"3474_CR76","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1007\/s40620-018-0552-9","volume":"32","author":"ML Reynolds","year":"2019","unstructured":"Reynolds ML, Nachman PH, Mooberry MJ, Crona DJ, Derebail VK (2019) Recurrent venous thromboembolism in primary membranous nephropathy despite direct Xa inhibitor therapy. J Nephrol 32:669\u2013672. https:\/\/doi.org\/10.1007\/s40620-018-0552-9","journal-title":"J Nephrol"},{"key":"3474_CR77","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1016\/j.ekir.2018.02.010","volume":"3","author":"DJ Sexton","year":"2018","unstructured":"Sexton DJ, de Freitas DG, Little MA, McHugh T, Magee C, Conlon PJ, O\u2019Seaghdha CM (2018) Direct-acting oral anticoagulants as prophylaxis against thromboembolism in the nephrotic syndrome. Kidney Int Rep 3:784\u2013793. https:\/\/doi.org\/10.1016\/j.ekir.2018.02.010","journal-title":"Kidney Int Rep"},{"key":"3474_CR78","doi-asserted-by":"publisher","first-page":"2153","DOI":"10.1016\/j.athoracsur.2008.02.037","volume":"85","author":"BD Spiess","year":"2008","unstructured":"Spiess BD (2008) Treating heparin resistance with antithrombin or fresh frozen plasma. Ann Thorac Surg 85:2153\u20132160. https:\/\/doi.org\/10.1016\/j.athoracsur.2008.02.037","journal-title":"Ann Thorac Surg"},{"key":"3474_CR79","doi-asserted-by":"publisher","first-page":"739","DOI":"10.3892\/etm.2017.5471","volume":"15","author":"L Zhang","year":"2018","unstructured":"Zhang L, Zhang H, Zhang J, Tian H, Liang J, Liu Z (2018) Rivaroxaban for the treatment of venous thromboembolism in patients with nephrotic syndrome and low AT-III: a pilot study. Exp Ther Med 15:739\u2013744. https:\/\/doi.org\/10.3892\/etm.2017.5471","journal-title":"Exp Ther Med"},{"key":"3474_CR80","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1161\/circulationaha.116.021890","volume":"134","author":"CB Fordyce","year":"2016","unstructured":"Fordyce CB, Hellkamp AS, Lokhnygina Y, Lindner SM, Piccini JP, Becker RC, Berkowitz SD, Breithardt G, Fox KA, Mahaffey KW, Nessel CC, Singer DE, Patel MR (2016) On-treatment outcomes in patients with worsening renal function with rivaroxaban compared with warfarin: insights from ROCKET AF. Circulation 134:37\u201347. https:\/\/doi.org\/10.1161\/circulationaha.116.021890","journal-title":"Circulation"},{"key":"3474_CR81","doi-asserted-by":"publisher","first-page":"2481","DOI":"10.1016\/j.jacc.2015.03.577","volume":"65","author":"M B\u00f6hm","year":"2015","unstructured":"B\u00f6hm M, Ezekowitz MD, Connolly SJ, Eikelboom JW, Hohnloser SH, Reilly PA, Schumacher H, Brueckmann M, Schirmer SH, Kratz MT, Yusuf S, Diener HC, Hijazi Z, Wallentin L (2015) Changes in renal function in patients with atrial fibrillation: an analysis from the RE-LY trial. J Am Coll Cardiol 65:2481\u20132493. https:\/\/doi.org\/10.1016\/j.jacc.2015.03.577","journal-title":"J Am Coll Cardiol"}],"container-title":["International Urology and Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-023-03474-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11255-023-03474-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-023-03474-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,26]],"date-time":"2023-06-26T12:35:39Z","timestamp":1687782939000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11255-023-03474-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,9]]},"references-count":81,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2023,7]]}},"alternative-id":["3474"],"URL":"https:\/\/doi.org\/10.1007\/s11255-023-03474-8","relation":{},"ISSN":["1573-2584"],"issn-type":[{"value":"1573-2584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,9]]},"assertion":[{"value":"21 November 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 February 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors certify that they have no affiliations with or involvement in any organization or entity with any financial interest or non-financial interest in the subject matter or materials discussed in this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}